explore -WSS

explore

author：hotspot 2025-09-05 13:41:51 - browse：1627

3D DNA on a sheet of paper listing nucleic acid sequences — coverage from STAT — Adobe

Ultima Genomics, an upstart some observers have called a “dark horse” in the world of DNA sequencing, will soon launch a line of high-power instruments that can read a human genome for as little as $100, the company’s leadership told STAT.

The sequencer, dubbed the UG 100, is a $1.5 million machine that can read up to 20,000 human genomes a year. The reagents required to operate the instrument cost as little as $1 per billion sequenced DNA bases; that translates to $100 per genome assuming each base in the 3-gigabase human genome is read 33 times, a common industry standard. The company plans to officially launch the product at this year’s Advances in Genome Biology and Technology meeting, which kicks off in Orlando, Fla., on Feb. 5.

The product’s cost and maximum output put it roughly in the same range as a line of high-throughput instruments launched in September 2022 by Illumina, which controls an estimated 80% of the sequencing market. But Ultima is hoping it can chip into the sequencing giant’s market share among genome centers, large clinical labs, and others with an appetite for reams of genetic data by offering lower operating costs and greater flexibility.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： U.K. researchers warn about biases in medical devices, algorithms

leisure time

WSS

Positive childhood experiences can help future health

Nurses recount patients attacks

RaDonda Vaught to speak at CommonSpirit event on patient safety

Leading voice in opioid treatment defends methadone clinic system

SCOTUS questions limit to govt efforts to fight misinformation

International team creates first chimeric human

entertainment

explore

focus

Supreme Court strikes down use of affirmative action

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

BioMarin wins approval for gene therapy to treat hemophilia A

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Cancer drug shortages should be causing more outrage

Plastic surgeons increase patient psychiatric screenings

As demand for Covid shots wanes, Moderna seeks its next success

Creating egg and sperm cells from stem cells raises ethical issues

New air purifier tech could be key to improving indoor air quality

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

leisure time

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

International team creates first chimeric human

5 to watch: Tech startups trying to solve health care's staffing crisis

Obesity now affects over 1 billion people worldwide, study finds

Gene editing the human germline: What are the risks?

Medical device lobby: We're tired of waiting on Medicare coverage

leisure time

focus

hotspot

focus